Annals of Surgical Oncology

, Volume 25, Issue 3, pp 709–719 | Cite as

Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for the Elderly: Is It Reasonable? A Meta-Analysis

  • Johan Gagnière
  • Julie Veziant
  • Bruno Pereira
  • Denis Pezet
  • Bertrand Le Roy
  • Karem Slim
Gastrointestinal Oncology
  • 156 Downloads

Abstract

Background

Whether cytoreductive surgery (CRS) plus hyperthermic intraperitoneal chemotherapy (HIPEC) is safe and worthwhile for elderly patients remains unclear. This meta-analysis of outcomes after CRS plus HIPEC for the elderly aimed to generate a higher level of evidence and precise indications for these patients.

Methods

A systematic literature search for studies reporting postoperative outcomes after CRS plus HIPEC for elderly patients was performed in the MEDLINE, Cochrane Central Register of Controlled Trials, ClinicalTrials.gov, Web of Knowledge Conference Proceedings Citation Index-Science, and Google Scholar databases. The included studies evaluated the overall 30-day postoperative morbidity, 90-day postoperative mortality, grade 3 or higher postoperative morbidity, rates of anastomotic leaks, reoperation and readmission, and length of hospital stay.

Results

The inclusion criteria were met by 13 retrospective studies involving 2544 patients. Considering only comparative studies, the 90-day postoperative mortality was significantly increased for elderly patients [odds ratio (OR), 0.49; 95% confidence interval (CI), 0.27–0.88; I 2 = 79%]. The 30-day grade 3 or higher postoperative morbidity was increased in the patients 70 years of age or older (14.5%; 95% CI 8.1–24.4 vs. 32.3%; 95% CI 22.4–44.0%; p = 0.004; I 2 = 85%). The overall 30-day postoperative morbidity, rates of anastomotic leaks, reoperation and readmission, and length of hospital stay were not affected by age.

Conclusions

Treatment of the elderly with CRS plus HIPEC was associated with increased severe postoperative morbidity and mortality. However, these conclusions should be weighted given the existence of major biases in the included studies. Age alone probably would not be a formal contraindication, but frailty should be taken into account. Further prospective studies are needed.

Notes

Disclosures

No conflicts of interest or funding to disclose for this study.

Supplementary material

10434_2017_6313_MOESM1_ESM.docx (38 kb)
Supplementary material 1 (DOCX 38 kb)
10434_2017_6313_MOESM2_ESM.tif (60 kb)
Supplementary material 2 (TIFF 59 kb) Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) flow chart of the literature search

References

  1. 1.
    Lutz W, Sanderson W, Scherbov S. The coming acceleration of global population ageing. Nature. 2008;451:716–19.CrossRefPubMedGoogle Scholar
  2. 2.
    Chia CS, You B, Decullier E, et al. Patients with peritoneal carcinomatosis from gastric cancer treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: is cure a possibility? Ann Surg Oncol. 2016;23:1971–9.CrossRefPubMedGoogle Scholar
  3. 3.
    Chua TC, Moran BJ, Sugarbaker PH, et al. Early- and long-term outcome data of patients with pseudomyxoma peritonei from appendiceal origin treated by a strategy of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. J Clin Oncol. 2012;30:2449–56.CrossRefPubMedGoogle Scholar
  4. 4.
    Goere D, Malka D, Tzanis D, et al. Is there a possibility of a cure in patients with colorectal peritoneal carcinomatosis amenable to complete cytoreductive surgery and intraperitoneal chemotherapy? Ann Surg. 2013;257:1065–71.CrossRefPubMedGoogle Scholar
  5. 5.
    Yan TD, Deraco M, Baratti D, et al. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for malignant peritoneal mesothelioma: multi-institutional experience. J Clin Oncol. 2009;27:6237–42.CrossRefPubMedGoogle Scholar
  6. 6.
    Adam R, Frilling A, Elias D, et al. Liver resection of colorectal metastases in elderly patients. Br J Surg. 2010;97:366–76.CrossRefPubMedGoogle Scholar
  7. 7.
    Gerstenhaber F, Grossman J, Lubezky N, et al. Pancreaticoduodenectomy in elderly adults: is it justified in terms of mortality, long-term morbidity, and quality of life? J Am Geriatr Soc. 2013;61:1351–7.CrossRefPubMedGoogle Scholar
  8. 8.
    Ide T, Miyoshi A, Kitahara K, Noshiro H. Prediction of postoperative complications in elderly patients with hepatocellular carcinoma. J Surg Res. 2013;185:614–9.CrossRefPubMedGoogle Scholar
  9. 9.
    Melis M, Marcon F, Masi A, et al. The safety of a pancreaticoduodenectomy in patients older than 80 years: risk vs. benefits. HPB Oxford. 2012;14:583–8.CrossRefPubMedPubMedCentralGoogle Scholar
  10. 10.
    Al-Refaie WB, Parsons HM, Henderson WG, et al. Major cancer surgery in the elderly: results from the American College of Surgeons National Surgical Quality Improvement Program. Ann Surg. 2010;251:311–8.CrossRefPubMedGoogle Scholar
  11. 11.
    Marusch F, Koch A, Schmidt U, et al. The impact of the risk factor “age” on the early postoperative results of surgery for colorectal carcinoma and its significance for perioperative management. World J Surg. 2005;29:1013–21; discussion 1021–1012.CrossRefPubMedGoogle Scholar
  12. 12.
    Shahir MA, Lemmens VE, van de Poll-Franse LV, Voogd AC, Martijn H, Janssen-Heijnen ML. Elderly patients with rectal cancer have a higher risk of treatment-related complications and a poorer prognosis than younger patients: a population-based study. Eur J Cancer. 2006;42:3015–21.CrossRefPubMedGoogle Scholar
  13. 13.
    Faivre J, Lemmens VE, Quipourt V, Bouvier AM. Management and survival of colorectal cancer in the elderly in population-based studies. Eur J Cancer. 2007;43:2279–84.CrossRefPubMedGoogle Scholar
  14. 14.
    Alyami M, Lundberg P, Kepenekian V, et al. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal carcinomatosis in the elderly: a case-controlled, multicenter study. Ann Surg Oncol. 2016;23(5):737–45.CrossRefPubMedGoogle Scholar
  15. 15.
    Beckert S, Struller F, Horvath P, Falcke A, Konigsrainer A, Konigsrainer I. Overall morbidity but not mortality is increased in elderly patients following cytoreductive surgery and HIPEC. Langenbeck’s Arch Surg/Deutsche Gesellschaf Chir. 2015;400:693–8.CrossRefGoogle Scholar
  16. 16.
    Cascales-Campos P, Gil J, Gil E, et al. Cytoreduction and HIPEC after neoadjuvant chemotherapy in stage IIIC–IV ovarian cancer: critical analysis in elderly patients. Eur J Obstet Gynecol Reprod Biol. 2014;179:88–93.CrossRefPubMedGoogle Scholar
  17. 17.
    Cascales-Campos PA, Lopez-Lopez V, Munoz-Casares FC, et al. Morbidity and mortality outcomes after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in patients aged 75 years and over: Spanish group of peritoneal cancer surgery (GECOP) multicenter study. Surg Oncol. 2016;25:111–6.CrossRefPubMedGoogle Scholar
  18. 18.
    Delotte J, Arias T, Guerin O, et al. Hyperthermic intraperitoneal chemotherapy for the treatment of recurrent ovarian cancer in elderly women. Acta Obstet Gynecol Scand. 2015;94:435–9.CrossRefPubMedGoogle Scholar
  19. 19.
    Huang Y, Alzahrani NA, Liauw W, Morris DL. Repeat cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for recurrent diffuse malignant peritoneal mesothelioma. Eur J Surg Oncol. 2015;41:1373–8.CrossRefPubMedGoogle Scholar
  20. 20.
    Klaver YL, Chua TC, de Hingh IH, Morris DL. Outcomes of elderly patients undergoing cytoreductive surgery and perioperative intraperitoneal chemotherapy for colorectal cancer peritoneal carcinomatosis. J Surg Oncol. 2012;105:113–8.CrossRefPubMedGoogle Scholar
  21. 21.
    Macri A, Saladino E, Trimarchi G, et al. Cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy in elderly patients. In vivo Athens Greece. 2011;25:687–90.Google Scholar
  22. 22.
    Mueller H, Hahn M, Simsa J. Cytoreductive surgery in the elderly patients: is it feasible? Hepatogastroenterology. 2008;55:2005–11.PubMedGoogle Scholar
  23. 23.
    Spiliotis JD, Halkia E, Boumis VA, Vassiliadou DT, Pagoulatou A, Efstathiou E. Cytoreductive surgery and HIPEC for peritoneal carcinomatosis in the elderly. Int J Surg Oncol. 2014;2014:987475.PubMedPubMedCentralGoogle Scholar
  24. 24.
    Tabrizian P, Jibara G, Shrager B, et al. Outcomes for cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in the elderly. Surg Oncol. 2013;22:184–9.CrossRefPubMedGoogle Scholar
  25. 25.
    Votanopoulos KI, Newman NA, Russell G, et al. Outcomes of cytoreductive surgery (CRS) with hyperthermic intraperitoneal chemotherapy (HIPEC) in patients older than 70 years: survival benefit at considerable morbidity and mortality. Ann Surg Oncol. 2013;20:3497–503.CrossRefPubMedGoogle Scholar
  26. 26.
    Kitai T, Yamanaka K, Miyauchi Y, Kawashima M. Indications for cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in elderly patients with peritoneal malignancy. Int J Clin Oncol. 2017;22(3):519–25.CrossRefPubMedGoogle Scholar
  27. 27.
    Lopez-Lopez V, Cascales-Campos PA, Schneider MA, et al. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC) in elderly patients: a systematic literature review. Surg Oncol. 2016;25:378–84.CrossRefPubMedGoogle Scholar
  28. 28.
    Moher D, Liberati A, Tetzlaff J, Altman DG, Group P. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med. 2009;6:e1000097.CrossRefGoogle Scholar
  29. 29.
    Slim K, Nini E, Forestier D, Kwiatkowski F, Panis Y, Chipponi J. Methodological index for non-randomized studies (minors): development and validation of a new instrument. ANZ J Surg. 2003;73:712–6.CrossRefPubMedGoogle Scholar
  30. 30.
    Dindo D, Demartines N, Clavien PA. Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg. 2004;240:205–13.CrossRefPubMedPubMedCentralGoogle Scholar
  31. 31.
    Huang Y, Alzahrani NA, Alzahrani SE, Zhao J, Liauw W, Morris DL. Cytoreductive surgery and perioperative intraperitoneal chemotherapy for peritoneal carcinomatosis in the elderly. World J Surg Oncol. 2015;13:262.CrossRefPubMedPubMedCentralGoogle Scholar
  32. 32.
    Bergman L, Dekker G, van Leeuwen FE, Huisman SJ, van Dam FS, van Dongen JA. The effect of age on treatment choice and survival in elderly breast cancer patients. Cancer. 1991;67:2227–34.CrossRefPubMedGoogle Scholar
  33. 33.
    Christman K, Muss HB, Case LD, Stanley V. Chemotherapy of metastatic breast cancer in the elderly: the Piedmont Oncology Association experience (see comment). JAMA. 1992;268:57–62.CrossRefPubMedGoogle Scholar
  34. 34.
    Hurria A, Leung D, Trainor K, Borgen P, Norton L, Hudis C. Factors influencing treatment patterns of breast cancer patients age 75 and older. Crit Rev Oncol Hematol. 2003;46:121–6.CrossRefPubMedGoogle Scholar
  35. 35.
    Newcomb PA, Carbone PP (1993) Cancer treatment and age: patient perspectives. J Natl Cancer Inst. 85:1580–84.CrossRefPubMedGoogle Scholar
  36. 36.
    Schrag D, Cramer LD, Bach PB, Begg CB. Age and adjuvant chemotherapy use after surgery for stage III colon cancer. J Natl Cancer Inst. 2001;93:850–7.CrossRefPubMedGoogle Scholar
  37. 37.
    Dent E, Kowal P, Hoogendijk EO. Frailty measurement in research and clinical practice: a review. Eur J Intern Med. 2016;31:3–10.CrossRefPubMedGoogle Scholar
  38. 38.
    Kenis C, Bron D, Libert Y, et al. Relevance of a systematic geriatric screening and assessment in older patients with cancer: results of a prospective multicentric study. Ann Oncol. 2013;24:1306–12.CrossRefPubMedGoogle Scholar
  39. 39.
    Rao AV, Hsieh F, Feussner JR, Cohen HJ. Geriatric evaluation and management units in the care of the frail elderly cancer patient. J Gerontol A Biol Sci Med Sci. 2005;60:798–803.CrossRefPubMedGoogle Scholar
  40. 40.
    Stuck AE, Siu AL, Wieland GD, Adams J, Rubenstein LZ. Comprehensive geriatric assessment: a meta-analysis of controlled trials. Lancet. 1993;342:1032–6.CrossRefPubMedGoogle Scholar
  41. 41.
    Participants P, Audisio RA, Pope D, et al. Shall we operate? Preoperative assessment in elderly cancer patients (PACE) can help: a SIOG surgical task force prospective study. Crit Rev Oncol Hematol. 2008;65:156–63.CrossRefGoogle Scholar
  42. 42.
    Fagard K, Leonard S, Deschodt M, et al. The impact of frailty on postoperative outcomes in individuals aged 65 and over undergoing elective surgery for colorectal cancer: a systematic review. J Geriatr Oncol. 2016;7:479–91.CrossRefPubMedGoogle Scholar
  43. 43.
    Robinson TN, Walston JD, Brummel NE, et al. Frailty for surgeons: review of a National Institute on Aging Conference on Frailty for Specialists. J Am Coll Surg. 2015;221:1083–92.CrossRefPubMedPubMedCentralGoogle Scholar
  44. 44.
    Kristjansson SR, Nesbakken A, Jordhoy MS, et al. Comprehensive geriatric assessment can predict complications in elderly patients after elective surgery for colorectal cancer: a prospective observational cohort study. Crit Rev Oncol Hematol. 2010;76:208–17.CrossRefPubMedGoogle Scholar
  45. 45.
    Makary MA, Segev DL, Pronovost PJ, et al. Frailty as a predictor of surgical outcomes in older patients. J Am Coll Surg. 2010;210:901–8.CrossRefPubMedGoogle Scholar
  46. 46.
    Robinson TN, Eiseman B, Wallace JI, et al. Redefining geriatric preoperative assessment using frailty, disability, and co-morbidity. Ann Surg. 2009;250:449–55.PubMedGoogle Scholar

Copyright information

© Society of Surgical Oncology 2017

Authors and Affiliations

  • Johan Gagnière
    • 1
    • 2
  • Julie Veziant
    • 1
    • 2
  • Bruno Pereira
    • 3
  • Denis Pezet
    • 1
    • 2
  • Bertrand Le Roy
    • 1
  • Karem Slim
    • 1
  1. 1.Department of Digestive and Hepatobiliary SurgeryUniversity Hospital of Clermont-FerrandClermont-FerrandFrance
  2. 2.U1071 INSERM, Université Clermont-AuvergneClermont-FerrandFrance
  3. 3.Biostatistics, Délégation à la Recherche Clinique et à l’InnovationUniversity Hospital of Clermont-FerrandClermont-FerrandFrance

Personalised recommendations